GLP-1 use tied to lower heart, thrombotic risk in adults with obesity, autoimmune disease

NEW ORLEANS — Individuals with obesity and autoimmune diseases who use a GLP-1 receptor agonist may have lower risk for mortality, fewer cardiovascular and thrombotic events and lower health care utilization, researchers reported. Among adults with obesity and at least one autoimmune disease, those who used a GLP-1 had a 44% lower risk for all-cause mortality, 31% lower risk for pulmonary